Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OX40 (CD134/TNFRSF4) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OX40 ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CD134/OX40/TNFRSF4 Products |
| OX40L (TNFSF4) – Ligand | OX40L ECD-Fc Protein. Native-like trimeric structure for receptor competition and blocking assays. | View OX40L Products |
| Gene Delivery | OX40 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. NF-κB reporter assay ready. Ideal for receptor clustering assays. | View CD134/OX40/TNFRSF4 Products |
| Benchmark Ab | Anti-OX40 (Sequence of Rocatinlimab / Amlitelimab / BMS-986178 Biosimilar). Recombinant positive control for antagonist and agonist reference. High purity. | View CD134/OX40/TNFRSF4 Products |
| Validator | OX40 siRNA Set. For knockdown verification and specificity checks. | View CD134/OX40/TNFRSF4 Products |
| Related Target: PD-1 (PDCD1) | Synergistic immune checkpoint for combination therapy or bispecific development. | View PD-1 Products |
| Related Target: GITR (TNFRSF18) | Parallel costimulatory pathway. Critical for off-target selectivity screening. | View GITR Products |
| Related Target: 4-1BB (TNFRSF9/CD137) | Competing TNFR superfamily target. Cross-reactivity panel essential. | View 4-1BB Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Trimerization Requirement (TNFRSF biology) | Native glycosylation HEK293 system preserves conformational epitopes required for agonist-induced clustering. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. Theoretical MW confirmed. |
| Receptor-Ligand Blocking Assays | HEK293 expressed ECD-Fc ensures native folding for accurate OX40-OX40L interaction analysis. |
| TNFR Superfamily Selectivity (GITR, 4-1BB, CD27) | Homolog panel proteins strictly verified by mass spec. Theoretical MW confirmed. |
| Agonist vs Antagonist Mechanism Distinction | Lentivirus for stable NF-κB reporter lines. Functional validation of signaling bias. |
| Lack of Reliable Controls | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks. Endotoxin controlled <1 EU/µg. |
Live R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OX40 therapeutics is intensifying, with major players shifting focus from systemic agonism to tumor-localized activation and autoimmune blockade. First-generation agonist monotherapies faced hepatic toxicity and limited efficacy, driving next-wave strategies: conditionally activated formats (e.g., PRO-AG, T-cell engagers) and combination with PD-1/PD-L1 inhibitors. Concurrently, antagonist antibodies for autoimmune diseases (atopic dermatitis, asthma, rheumatoid arthritis, SLE) are advancing, exemplified by Rocatinlimab (Amgen/Kyowa Kirin) and Amlitelimab (Sanofi). Key R&D directions include Fc-engineered selective depleting vs. non-depleting profiles, and bispecifics (OX40 x PD-L1) to confine immune activation to the tumor microenvironment. The field is bifurcating: oncology agonists require receptor clustering and FcγR engagement; autoimmune antagonists demand complete OX40-OX40L blockade. This paradigm shift necessitates distinct assay solutions for trimerization, cross-species reactivity, and superfamily selectivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAb | BMS, GSK, Pfizer, Iovance, Agenus | Solid Tumors (NSCLC, Melanoma) | Receptor Clustering Assay (Need high-purity ECD-Fc for SPR/BLI oligomerization studies) |
| Fc-Enhanced Agonist | Iovance (IOV-3510) | Advanced Melanoma | FcγR Binding Assay (Need IgG1/IgG4 isoforms with modified Fc) |
| Bispecific (PD-L1/OX40) | Inhibrx, F-star, Macrogenics (MGD013) | Immunotherapy Refractory | Heterodimer Validation (Need Cross-reactive Abs & dual-target cells) |
| Antagonist (Autoimmune) | Amgen/Kyowa Kirin, Sanofi | Atopic Dermatitis, Asthma, Rheumatoid Arthritis, SLE | Ligand Competition Assay (Need high-purity OX40L for blocking validation) |
| Cell Therapy (CAR-T) | Academic / Preclinical | Hematologic Malignancies | Expression Validation (Lentivirus for stable overexpression lines) |
Note: All View ... Products placeholders represent direct links to TarMart product pages. Live tracker links provide up-to-date external resources.